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Abstract 
All living organisms depend on the metabolism of carbohydrates for energy and the 
biosynthesis of necessary glycoconjugates. One of these carbohydrates is the 
monosaccharide galactose. Galactose is metabolized by humans through the Leloir 
pathway of galactose metabolism, which contains three enzymes to modify galactose so 
that it can be incorporated into glycolysis for the production of cellular energy. The 
middle enzyme of this pathway, galactose-1-phosphate uridyltransferase, produces 
uridine diphosphogalactose (UDP-gal) from galactose-1-phosphate (gal-1P), and a 
deficiency of this enzyme results in the human disease galactosemia. Galactosemia is 
diagnosed soon after an infant begins feeding, and although a galactose-restricted diet 
eliminates immediate acute symptoms, long-term complications typically persist. The 
exact mechanism of galactosemia pathogenesis is not currently understood, but research 
is being performed concerning the possible involvement of the unfolded protein response 
(UPR), human inositol monophosphatase (hIMPase), and abnormal glycan composition 
of enzymes, hormones, and growth factors. Future research of GALT and galactosemia 
will aim to better understand the pathogenesis of galactosemia with hopes of a more 
effective treatment to decrease long-term complications of the disease.  
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Introduction 
All living organisms must utilize sugars, or carbohydrates, for the production of 
cellular energy and the synthesis of necessary cellular glycoconjugates. Humans not only 
consume dietary carbohydrates, but can also synthesize modified carbohydrate monomers 
using reversible metabolic pathways. Galactose is a carbohydrate monomer typically 
consumed as a part of the dissacharide lactose in the human diet. The human body 
metabolizes and utilizes galactose via the Leloir pathway of galactose metabolism. This 
pathway includes three main enzymes, each of which produces a different metabolic 
intermediate with the goal of incorporating galactose into glycolysis for energy 
production. The middle enzyme of the Leloir pathway is galactose-1-phosphate uridyl 
transferase (GALT), which produces uridine diphosphogalactose (UDP-gal) from 
galactose 1-phosphate (gal-1P). UDP-gal can continue in the Leloir pathway to 
eventually be used for energy production, but it is also used to synthesize numerous 
necessary glycoconjugates. GALT deficiency in humans results in galactosemia, a 
potentially fatal disease if not dealt with immediately from birth. The exact disease 
mechanism of galactosemia is not yet completely understood, but possible models of 
pathogenesis have been proposed and will be described in this review.  
The Leloir Pathway 
The Leloir pathway is the only mechanism of galactose metabolism in both 
humans and yeast, and has been extensively studied and characterized using both a yeast 
model and an Escherichia coli (E. coli) model (Grossiord, Luesink, Vaughan, Arnaud, & 
de Vos, 2003; Kalckar, Kurahashi, & Jordan, 1959; T. Slepak, Tang, Addo, & Lai, 2005; 
Yarmolinsky, Wiesmeyer, Kalckar, & Jordan, 1959). Kalckar, Kurahashi, & Jordan 
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named and characterized the Leloir pathway in 1959 while studying a strain of E. coli K-
12 defective in galactose metabolism and unable to grow on galactose-containing media. 
Three enzymes, galactokinase (GALK), galactose-1-phosphate uridyl transferase 
(GALT), and galactose-4-epimerase (GALE), and their respective mechanisms were 
discovered and defined (Kalckar et al., 1959).  
Upon entry into the cell, galactose is first phosphorylated by GALK to produce 
galactose-1-phosphate (gal-1P), which is one of the two substrates of GALT. GALT 
produces one uridine diphosphoglactose (UDP-gal) and one glucose-1-phosphate (glu-
1P) from one uridine diphosphoglucose (UDP-glu) and one gal-1P. The desired product 
of GALT, UDP-gal, is the substrate of GALE. GALE epimerizes UDP-gal to produce 
UDP-glu, which can then be modified further for entry into glycolysis or used as UDP-
glu to synthesize necessary glycoconjugates in the cell (Grossiord et al., 2003; Kalckar et 
al., 1959; Mollet & Pilloud, 1991). Further modification of UDP-glu involves the loss of 
uridine monophosphate to produce glu-1P, then the action of a mutase enzyme to produce 
glucose-6-phosphate, a glycolytic intermediate that enters glycolysis for energy 
production in the form of ATP (Grossiord et al., 2003). Not all UDP-gal produced is 
epimerized to UDP-glu by GALE. Because galactose is an essential component of many 
glycoconjugates, some UDP-gal is used for the synthesis of these sugar moieties. The 
UDP form of these sugars is necessary for use in glycoconjugate synthesis, highlighting 
the importance of GALT function in the metabolism and cellular use of galactose (Lai, 
Langley, Khwaja, Schmitt, & Elsas, 2003).  
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GALT Mechanism of Function 
GALT, the second enzyme of the Leloir pathway, is a dimeric enzyme, consisting 
of two identical subunits and encoded for on chromosome 9 in humans. Each of these 
subunits is 379 amino acid residues in length and has one active site for catalytic activity. 
Both subunits function to carry out the same reaction simultaneously, allowing for more 
efficient production of UDP-gal. 
GALT functions via the double-displacement mechanism of ping-pong kinetics. 
In this mechanism, the enzyme is first modified by one substrate to produce the first 
product before acting on the second substrate to return to its original state and produce 
the second, desired product. In the case of GALT, the first substrate is UDP-glu. The 
active site of GALT contains a histidine amino acid residue, found in humans as the 186th 
amino acid in the protein’s primary sequence. UDP-glu binds to this histidine, resulting 
in the release of glu-1P and the modification of GALT with the addition of a UMP group 
to the histidine residue (uridine monophosphohistidine, or his-UMP). Gal-1P can then 
bind to the uridyl-enzyme intermediate, allowing the enzyme to transfer the UMP group 
from histidine to gal-1P and produce UDP-gal. The enzyme is then reset to its original 
state, and can repeat the reaction.  
GALT Deficiency 
GALT deficiency produces metabolic complications in almost all organisms that 
utilize the enzyme. Yarmolinsky et al. were among the first to study such deficiency, and 
did so using E. coli sensitive to the presence of galactose (Yarmolinsky et al., 1959). 
Results showed that of the three enzymes in the Leloir pathway, only a deficiency of 
GALT could produce the negative effects associated with galactose-sensitivity, namely 
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growth inhibition (Yarmolinsky et al., 1959). In humans, GALT deficiency typically 
results from a mutation in the gene encoding the GALT enzyme. The most common 
mutation in humans involves a point mutation at amino acid residue 188, causing a 
glutamine residue to be translated as an arginine residue (Tyfield et al., 1999). The 
displacement of glutamine, a moderately hydrophilic amino acid, with arginine, a basic, 
positively charged amino acid, results in a change in charge and therefore enzymatic 
conformation only two residues away from the active site of the enzyme, leading to 
inactivity of the enzyme. Individuals homozygous for this mutation or another mutation 
causing loss of enzyme activity have complete or almost complete loss of GALT activity, 
a condition known as galactosemia (Arn, 2003). 
Galactosemia 
Galactosemia is a human disease resulting from loss of GALT activity in 
galactose metabolism. The disease is typically diagnosed soon after birth, as breast-
feeding infants are consuming lactose via breast milk or formula. Lactose, when 
metabolized, produces one glucose and one galactose monomer per lactose molecule. The 
glucose monomer is metabolized via glycolysis, but the galactose monomer, when fed 
through the galactose metabolic pathway, cannot be metabolized past gal-1P. Disease 
symptoms arise in infants soon after they begin feeding, and a diagnosis can be made. 
Pathogenesis of galactosemia is not completely understood, although several mechanisms 
of the disease processes have been proposed (Charlwood, Clayton, Keir, Mian, & 
Winchester, 1998; Lai & Elsas, 2000; Lai et al., 2003; Liu et al., 2012; Sturiale et al., 
2005). Treatment currently involves management of diet, although some drug targets in 
the disease process have been proposed. 
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Diagnosis and Screening 
Galactosemia occurs about one in every 30,000 to 60,000 babies in the US and is 
typically diagnosed using newborn screening or via the observation of disease symptoms 
in an infant ("Expanded Newborn Screening Using Tandem Mass Spectrometry 
Financial, Ethical, Legal and Social Issues (FELSI)," 2013). Newborn screening for 
galactosemia and other inherited genetic disorders is available in all of the states and 
provinces of the United States, due to the high death rate associated with untreated 
individuals. For galactosemia screening involves testing infant blood and urine samples 
for the presence of GALT and galactose metabolites (Freer, Ficicioglu, & Finegold, 
2010). Samples are first tested for galactose concentration and GALT activity, and if 
galactose levels are high and/or GALT activity is low, the samples are also assayed for 
gal-1P and tested for some of the more common DNA mutations associated with 
galactosemia (Freer et al., 2010). GALT enzyme presence of less than 32 µmol/L (normal 
150-500 µmol/L) is usually indicative of GALT-deficient galactosemia (Freer et al., 
2010). Some states, such as Pennsylvania and New York, legally require all newborns to 
be screened for certain inherited genetic disorders, including galactosemia, within 24 to 
48 hours after birth, with results being reported seven to 10 days after the blood is taken 
and no charge being administered for the screening ("Conditions Screened by State," 
2013; "Pennsylvania Screening Services for Newborn Babies," 2012).  
Newborn screening is essential in detecting and treating galactosemia efficiently 
and before physical and mental damage has been done that cannot be reversed. One study 
found that about 80% of children given newborn screening for galactosemia were 
diagnosed within two weeks of age, compared to 35% that were not screened. Only 20% 
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of the children screened, however, were free of GALT deficiency symptoms at the time 
of diagnosis (Waggoner, Buist, & Donnell, 1990). More efficient and timely screening 
methods are necessary to decrease the cases of infants who are already exhibiting disease 
symptoms at the time of diagnosis.  
Description 
Because newborn screening is typically not performed until at least 24 hours after 
an infant has begun feeding, galactosemic infants will consume galactose before 
diagnosis and will likely show disease symptoms almost immediately. Acute symptoms 
of galactosemia observed in newborns who have begun milk feeding include poor 
feeding, vomiting, liver dysfunction, hypotonia and lethargy, cataracts, and predisposition 
to sepsis (Coman et al., 2010). Though uncommon due to effective newborn screening, 
undiagnosed galactosemia can lead to liver cirrhosis, mental retardation, and even death 
(Antshel, Epstein, & Waisbren, 2004). Patients with galactosemia have been found to 
have higher rates of ovarian failure, cataracts, speech and language impairments, and 
developmental delays, even with a monitored dietary intake (Antshel et al., 2004). A 
long-term study in Ireland, where galactosemia is most prevalent, followed 130 Irish 
galactosemic patients, all but eight of which were diagnosed with newborn screening. 
Ninety-two percent of these individuals were homozygous for the Q188R mutation. 
Hypergonadotropic hypogonadism (HH), a condition of hypogonadism as a result of an 
impaired response of the gonads to sex hormones, was seen in 91.2% of the females, and 
IQ was less than 89 for almost all of the 85 individuals that received IQ testing (Coss et 
al., 2013; Friedman, Barrows, & Kim, 1983). Although acute symptoms at birth can be 
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managed with diet, long-term outcomes involving impaired sexual and mental function 
are still prevalent among galactosemic individuals.  
A case report from 2012 described disease symptoms of a full-term male infant 
who was fed a lactose-containing formula from birth. After showing symptoms of 
lethargy and poor feeding around six days of life, newborn screening tests were 
performed on a dry blood spot from the second day of life, showing positive results for 
galactosemia at day eight of life. GALT activity in the infant was assayed and found to be 
absent, and galactose metabolites, such as galacticol and gal-1P, were found to be present 
in very high levels in the child. Galacticol accumulation in brain tissue led to acute 
encephalopathy, but with dietary treatment and fresh frozen plasma administration the 
encephalopathy cleared and the child was achieving normal growth and development at 
one year of age. Long-term follow-up with the child revealed delayed language 
acquisition, as well as speech defect and cognitive impairment (Berry, 2012). This study, 
like many others involving individual cases of galactosemia, describes the typical 
progression of disease for infants diagnosed with galactosemia in the first few days of 
life. What causes such complications and developmental impediments involves the 
pathogenesis of galactosemia, where much of the current research concerning this disease 
is taking place.  
Pathogenesis 
While the disease processes and mechanisms of galactosemia are not completely 
understood, numerous theories have been proposed. One of the most serious 
complications associated with galactosemia is neurological impairment, which can occur 
even in treated patients. This complication may result from either damage in utero, 
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damage that occurs before diagnosis and treatment, poor adherence to dietary restrictions, 
and/or accumulation of gal-1P even when adhering to dietary treatment (Antshel et al., 
2004). Almost all proposed mechanisms of galactosemic disease processes involve the 
build-up of galactose metabolites, namely gal-1P, as well as significantly decreased 
levels of UDP-gal. High levels of gal-1P (up to 3.3 mM) are found almost exclusively in 
galactosemic individuals, leading to the assumption that gal-1P plays an essential role in 
the pathogenesis of galactosemia (Lai et al., 2003). Gal-1P has been proposed to interfere 
with cellular enzymes, as well as induce cellular responses normally reserved for cellular 
stress. The low levels of UDP-gal also play a crucial role in the cellular dysfunction 
observed in galactosemia, as UDP-gal is an essential component of many important cell 
signaling molecules and other cellular receptors. When UDP-gal levels are low, the cell is 
forced to utilize other available sugars, changing the chemical make-up of these signals 
and receptors and leading to a lack of proper cellular function. 
Endoplasmic reticulum – the UPR. Slepak et al. conducted a study in 2009 to 
investigate the observation of induced endoplasmic reticulum stress in a human cell 
model of classic galactosemia (T. I. Slepak, Tang, Slepak, & Lai, 2007). Primary 
fibroblasts from three random galactosemic patients were used as the test environment, 
and three different growth conditions were tested. A hexose-free medium was used to 
rule out the possibility that glucose starvation caused the observed effects of GALT 
deficiency, and a hexose-free medium containing only 0.1% glucose was used to observe 
cell viability in the absence of galactose. Finally, cells were grown in hexose-free 
medium containing only 0.1% galactose to obtain a disease model with accumulation of 
the toxic metabolite gal-1P. Cells grown in the hexose-free medium alone did not grow 
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and detached from the plate surface on which they were initially attached, while cells 
grown in 0.1% glucose grew normally and were not affected by the GALT deficiency.  
Cells grown in 0.1% galactose showed accumulation of gal-1P similar to that 
observed in the erythrocytes of untreated galactosemic patients (T. I. Slepak et al., 2007). 
Continued experiments were performed only with this hexose-free, galactose-containing 
media. GALT-deficient and GALT-positive (normal GALT expression) cells were 
compared for behavior in the presence of galactose, with a concentration on gene 
expression in each cell type. Results showed the many of the same genes involved in the 
unfolded protein response (UPR) were upregulated in the GALT-deficient cells. The UPR 
functions in mammalian cells to respond to stress encountered by the endoplasmic 
reticulum when unfolded or improperly folded proteins begin to accumulate inside the 
endoplasmic reticulum. Transcriptional activators of the genes involved in the UPR were 
upregulated in the GALT-deficient cells grown in galactose, including CHOP, ATF4, 
ATF3, all of which increase transcription of the genes encoding ER resident proteins, 
lectins, and foldases (Schroder & Kaufman, 2005). Protein chaperones, lectins, and 
foldases function in the UPR to help ease endoplasmic reticulum stress by aiding the 
protein folding process, and if these molecules cannot resolve the stress adequately the 
cell tries to degrade the unfolded proteins by increasing transcription and translation of 
endoplasmic reticulum resident proteases, or protein-degrading enzymes (Eriksson et al., 
2004; Hosokawa, Wada, Natsuka, & Nagata, 2006). The master ER stress sensor protein, 
GRP78/BiP, was also found to be up-regulated in the GALT-deficient cells grown in 
galactose, and the amount of GRP78/BiP produced was proportional to the amount of 
galactose present in the medium. Because GRP78/BiP can also be induced in starvation, 
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GALT-deficient cells were also grown in medium containing galactose and glucose, 
which resulted in the same observation of GRP78/BiP up-regulation and showed that the 
up-regulation was a result of GALT-deficiency. Slepak et al. also investigated the 
observation that GALT-deficient cells grow slower than normal, even in the presence of 
glucose, by observing the levels of the fibroblast epidermal growth factor receptor 
(EGFR). EGFR was found to be present at much lower levels in GALT-deficient cells 
compared to normal fibroblasts, especially when the GALT-deficient cells were grown in 
galactose. EGFR protein synthesis and turnover are both related to the functional state of 
the ER, implying the role of ER stress in GALT-deficient cells in impeding proper 
growth factor function and therefore slowing cellular growth.  
Typically, ER stress is related to calcium homeostasis in the ER, as a disturbance 
in calcium homeostasis initiates ER stress. Slepak et al. analyzed the role of GALT-
deficiency in this process, and found that galactosemic cells experience much less free 
calcium release from the ER into the cytoplasm upon bradykinin addition (stimulates 
calcium release from the ER by activation of phospholipase C and IP3 release (Hashii, 
Nozawa, & Higashida, 1993)) (T. I. Slepak et al., 2007). The IP3 receptor presence was 
found to be unchanged, meaning the low levels of calcium release resulted from either 
altered levels of calcium in ER stores or lower levels of IP3 release due to a reduction of 
phosphatidylinositol diphosphate (PIP2), which will be discussed later.  
The connection between GALT-deficiency, galactose presence, and ER stress 
demonstrated by Slepak et al. was also explored in a study by De-Souza et. al. in 2014, 
which found that the UPR actually serves to protect galactosemic cells in the yeast model 
(De-Souza et al., 2014). Two different yeast models were utilized; one with a 
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dysfunctional copy of the GALT gene and the other treated with lithium and galactose. 
Lithium treatment with galactose growth conditions mimicked GALT-deficiency in 
galactosemic cells, as lithium inhibited phosphoglucomutase and allowed for the build-up 
of gal-1P. This study found first that gal-1P is required for the induction of the UPR 
observed in galactosemic cells. The GALK encoding gene of yeast was deleted in both 
models, resulting not only in the elimination of the unnecessary UPR activation, but also 
the disappearance of all toxic effects associated with galactosemic cells. The GALK-
deficient cells did not have an increased tolerance to other known stressors of the ER, 
implying that the elimination of the UPR did not result from increased tolerance to ER 
stress no matter what the source.  
Because the UPR is normally a protective response when cells undergo ER stress, 
De-Souza et al. investigated whether the UPR is also protective when activated in 
galactosemic cells. To test this, GALT-deficient yeast mutants were constructed that did 
not have the genes necessary for activating the UPR in yeast (ire1∆) and were compared 
to GALT-deficient cells that were still able to activate the UPR. Results showed that 
ire1∆ GALT-deficient mutants were even more sensitive to galactose than UPR-positive 
GALT mutants, while levels of gal-1P accumulation did not significantly differ between 
strains, indicating that increased gal-1P is not responsible for the increased galactose 
sensitivity in the absence of a functional UPR. Implications of this study indicate the 
importance of the UPR in the adaptation of yeast cells for survival in galactosemic 
conditions, but when applied to human galactosemic cells shows an antagonistic effect. 
The UPR may protect galactosemic cells initially, but a prolonged response initiates 
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apoptosis that kills the cell and may contribute to observed disease symptoms (De-Souza 
et al., 2014).  
While galactosemia-induced ER stress and the ensuing UPR are clearly affected 
by GALT-deficiency and gal-1P accumulation, the exact mechanism of the correlation 
remains unknown and requires further study. Implications made in the Slepak study 
indicate a possible interference of gal-1P with the normal function of human inositol 
monophosphatase (hIMPase) in IP3 signaling, as well as the possibility that a disruption 
in cellular glycoconjugate composition leads to or is involved in the lack of ERGF 
secreted by GALT-deficient galactosemic human fibroblasts (T. I. Slepak et al., 2007). 
Both of these possible galactosemic disease mechanisms have been studied to increase 
the understanding of exactly how gal-1P accumulation leads to the disease symptoms of 
galactosemia. 
Inositol monophosphatase disruption. hIMPase is an essential enzyme in the 
pathway of inositol synthesis from glucose-6-phosphate (glu-6P), directly converting glu-
6P to the intermediate molecule myo-inositol-1-phosphate (myo-inositol-1P). hIMPase 
can also perform the reverse reaction and hydrolyze myo-inositol-1P, making it a crucial 
enzyme for maintaining appropriate cellular levels of myo-inositol (Hallcher & Sherman, 
1980). Mehta et al. conducted a study in 1999 to observe the proposed relationship 
between gal-1P and hIMPase, specifically related to inositol mediated signaling in the 
brain and the possible correlation between this phenomenon and the neurological damage 
observed in galactosemic individuals (Mehta, Kabir, & Bhat, 1999). Using a yeast model 
expressing hIMPase, it was found that growing GALT-deficient yeast cells containing 
hIMPase on galactose-containing media allowed for cellular survival and growth on this 
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media, even though a more recent study has shown that GALT-deficient cells do not 
survive when grown on hexose-free media containing only galactose as the carbon source 
(T. I. Slepak et al., 2007). This positive growth was found to be a result of hIMPase 
presence and function, as addition of lithium, a known inhibitor of hIMPase, led to 
cessation of growth. Implications were that IMPase either reduces gal-1P accumulation or 
facilitates metabolism of galactose, or a combination of the two. Positive growth of 
GALT-deficient hIMPase containing yeast cells on media containing only galactose 
meant either galactose or gal-1P was being metabolized to lead to the elimination of 
galactose toxicity (Mehta et al., 1999). hIMPase expressing, GALT-deficient yeast cells 
lacking functional GALK were constructed to determine which metabolite the cells were 
utilizing. The GALK-deficient cells were unable to produce gal-1P, meaning if the cells 
grew on galactose-containing media then they were using galactose and not gal-1P. 
Results showed that the hIMPase GALT/GALK-deficient yeast cells were unable to grow 
on media containing only galactose, and gal-1P was inferred to be the metabolite 
allowing for growth of GALT-deficient cells containing hIMPase.  
To investigate the exact metabolic pathway of gal-1P utilization in these cells, the 
few possible enzymatic mechanisms were considered for obtaining glu-1P from gal-1P in 
the absence of GALT. The most likely pathway involved UDP-galactose 
pyrophosphorylase (UGalP), an enzyme that can reversibly convert gal-1P to UDP-gal, 
and UDP-glucose pyrophosphorylase (UGluP), which reversibly converts UDP-glu to 
glu-1P. Gal-1P would have to first be converted to UDP-gal with UGalP, after which 
GALE, still present and functional as it would normally be, converts UDP-gal to UDP-
glu, which is then converted to glu-1P by UGluP and metabolized via glycolysis. The 
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study confirmed that this pathway is utilized in yeast cells, and that overexpression of 
IMPase relieves galactose toxicity in GALT-deficient cells via modulation of UGlu/GalP 
activity. GALT-deficient cells with overexpressed hIMPase and grown in galactose had 
significantly greater UGalP activity compared to cells grown in glycerol and cells without 
overexpressed hIMPase, showing that hIMPase and galactose are independent positive 
modulators of UGalP activity (Mehta et al., 1999).  
The results of this study imply a strong connection between hIMPase activity and 
the utilization of accumulated gal-1P in GALT-deficient cells. In 2003, Bhat investigated 
the nature of the relationship between hIMPase and gal-1P, proposing that IMPase is a 
cross link between galactose metabolism and the phosphotidylinositolbisphosphate 
(PIP2) signaling pathway, and that this connection is at least partially responsible for the 
long-term neurological impairments seen in many galactosemic patients (Bhat, 2003). 
Gal-1P is typically a normal intermediate of galactose metabolism, but when allowed to 
accumulate in galactosemic individuals it also has the opportunity to interfere with 
IMPase activity. In the PIP2 signaling pathway, IMPase converts multiple 
inositolbisphosphates to inositol. This is especially important in brain tissue, as PIP2 
signaling is a vital second messenger for several neurotransmitters in the brain. PIP2 is 
hydrolyzed to produce diacylglycerol and inositol 1,4,5-triphosphate (IP3), two second 
messengers that activate protein kinase C and release internal stores of calcium. The rate 
of PIP2 signaling is dependent upon the regeneration of PIP2, and this synthesis relies 
directly on the amount of free inositol in the cell. The production of inositol by IMPase is 
a crucial part of driving the PIP2 signaling pathway, as free inositol is a necessary 
substrate of the pathway. Gal-1P interferes with inositol production by competing with 
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inositolbisphosphates as a substrate of IMPase, leading to decreased free inositol 
production and therefore less PIP2 signaling (Bhat, 2003; Parthasarathy, Parthasarathy, & 
Vadnal, 1997). Bhat also points out the possibility that the reversible function of UGalP 
is able to produce gal-1P in galactosemic individuals, even when the individual is on 
galactose-restricted diet and is consuming no dietary galactose. This production of gal-1P 
from a source other than galactose could explain the occurrence of long-term physical 
impairment, such as brain damage, in galactosemic patients on a galactose-restricted diet. 
Three specific enzymes – GALT, UGalP, and hIMPase – are proposed by Bhat to be 
primarily responsible for maintaining exact cellular concentrations of gal-1P in healthy 
individuals, and when one of these enzyme (GALT) is deficient, multiple cellular 
pathways are affected (Bhat, 2003).  
Relating the studies with IMPase to future studies conducted concerning the UPR 
reveals that alteration of calcium release, part of PIP2 signaling, is a factor in both. 
Changes in cytoplasmic calcium levels resulting from calcium release from the ER after 
IP3 production from PIP2, stimulated by bradykinin, was found to decrease significantly 
in galactosemic cells grown in galactose (De-Souza et al., 2014). Current research would 
imply that the decrease of calcium release is an indirect result of gal-1P accumulation, as 
gal-1P competitively inhibits IMPase, therefore decreasing free inositol in the cell and 
resulting in slower regeneration of PIP2 for IP3 production (Bhat, 2003; De-Souza et al., 
2014; Mehta et al., 1999).  
Low UDP-gal and changes in glycoconjugate composition. A third topic for 
study concerning galactosemia pathogenesis involves UDP-gal, another of the 
metabolites of galactose metabolism. UDP-gal is a common component of the synthesis 
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of numerous glycoconjugates in the cell, including signal receptors and signal molecules 
like hormones and growth factors. One such growth factor, ERGF, was studied and 
discussed previously in connection with the possible role of the UPR in galactosemia 
pathogenesis, as ERGF has sugar moieties that contain multiple galactose monomers in 
healthy individuals but may have altered composition (and therefore altered function) in 
galactosemic cells (T. I. Slepak et al., 2007). Multiple studies have been conducted 
concerning the extensive effects a lack of UDP-gal may have on the synthesis of multiple 
galactose-containing glycoconjugates, many of these studies implying that a change in 
the normal sugar composition is at least partially responsible for the disease symptoms of 
galactosemia. One such study by Charlwood et al. in 1997 investigated abnormal 
glycosylation of transferrin from galactosemic individuals, showing that the N-linked 
glycans of serum transferrin from human galactosemic cells are shortened from their 
normal length and usually end with N-acetylglucosamine (Charlwood et al., 1998). The 
analysis of galactosemic transferrin glycosylation compared to normal transferrin 
glycosylation showed that galactosemic transferrin was not only more heterogeneous in 
glycosylation sequence, but the glycans were also truncated. The most commonly 
observed, biantennary glycan associated with transferrin was observed to account for 
86% of all transferrin glycans in healthy individuals, but only 13% in galactosemic 
patients, the other 87% composed primarily of four different truncated glycans. Some of 
the galactosemic patients tested did show a significant increase in the common transferrin 
glycan (up to 82%) after a galactose-free diet was initiated, but others did not, leading to 
inconclusive data concerning galactosemia treatments involving diet in connection to 
normal glycosylation of cellular proteins.  
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Charlwood et al. also studied the specific structures of the truncated glycans 
found on galactosemic transferrin, finding that all four common truncated glycans 
observed consisted of the core pentasaccharide of most N-linked polysaccharides, three 
mannose residues and two N-acetylglucosamine residues, with slight modifications. N-
acetylglucosamine was typically found in place of normal residues, such as fructose or 
galactose, at the terminal, non-reducing ends of glycan branches, making the 
glycoproteins more favorable for acceptance of galactose residues (in the form of UDP-
gal) when available (Charlwood et al., 1998). No clear relationship was established 
between levels of gal-1P and normally-glycosylated transferrin, as dietary treatment 
decreased gal-1P concentration, but normal glycosylation percentages ranged from 18-
82%. The primary conclusion of this study revealed that the truncation of transferrin 
glycans in untreated galactosemic individuals was consistent with a decreased ability of 
the cells to galactosylate protein glycans. 
Stiurale et al. conducted a similar study in 2005 to further investigate 
hypogalactosylation of galactosemic cell glycoconjugates. They compare the abnormal 
isoform patterns of multiple enzymes and hormones associated with galactosemia to 
congenital disorders of glycosylation (CDG), which are genetic defects of glycan 
synthesis that affect either the assembly or processing of N-linked glycans (Sturiale et al., 
2005). The goal of this study was to analyze the glycosylation of serum transferrin, like 
Charlwood et al., then compare the results to CDG-affected and healthy individuals. 
Results partially confirmed the Charlwood study, showing that transferrin was 
hypoglycosylated and had an abnormal increase in fucosylation and branching of N-
linked glycans in galactosemic individuals. An interesting, somewhat conflicting result 
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compared to the Charlwood study was that abnormal N-glycan formation presented in the 
form of the loss of an entire N-linked oligosaccharide at one or both of the glycosylation 
sites on transferrin, rather than the loss or gain of an N-acetylglucosamine residue. 
Sturiale et al. also found that the extent of defective glycosylation is dependent on how 
long the galactosemic patient has been exposed to dietary galactose, and that a galactose-
free diet in these individuals is sufficient to eliminate abnormal transferrin N-glycan 
isoforms and return glycan compositions to normal (Sturiale et al., 2005).  
A study conducted by Lai et al. in 2003 sought to explain the glycosylation 
changes in galactosemic cells by studying the availability of UDP-gal in GALT-deficient 
human cells. Lai hypothesized that a deficiency of UDP-gal resulted from either a lack of 
cellular energy due to galactose not being metabolized, accumulated toxins like gal-1P, or 
a decreased production of essential UDP-hexoses, like UDP-gal (Lai et al., 2003). The 
study eliminated the first hypothesis, based on the finding that both normal cells and 
GALT-deficient cells were able to grow on hexose-free media supplemented only with 
fetal bovine serum (FBS). The second hypothesis, concerning gal-1P toxicity, was 
studied by comparing galactosemic cells with GALT-transfected cells, growing both in 
hexose-free media containing FBS and 0.1% galactose. Results showed that expression of 
GALT in GALT-deficient galactosemic cells allowed for growth on this media, while 
GALT-deficient cells were unable to grow, leading to the question of whether decreased 
presence of gal-1P or increased presence of UDP-gal was what led to viable growth of 
the GALT-deficient cells made to express GALT. UDP-hexose concentrations of GALT-
deficient cells grown on a galactose-containing media were found to decrease 
substantially after only 24 hours, even though these levels started out below normal 
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before growth in galactose, and gal-1P levels in these cells increased markedly during 
growth on galactose. Lai observed that the addition of human UDP-glucose 
pyrophosphorylase (hUGP2), an enzyme that functions to produce UDP-glucose from 
glu-1P and UTP, to GALT-deficient cells aided in decreasing gal-1P concentrations and 
allowed for cell growth and viability on galactose (Lai & Elsas, 2000; Lai et al., 2003). 
hUGP2 was found to utilize gal-1P as a substrate to produce UDP-gal, but with a very 
high Km, meaning hUGP2 will only act on gal-1P at high concentrations, otherwise 
preferably utilizing glu-1P as a substrate. GALT was also found to have a much higher 
capacity for UDP-gal synthesis from gal-1P (about 1000-times higher rate), making it by 
far the more effective enzyme for UDP-gal production compared to hUGP2; however, 
overexpression of hUGP2 in experimental cells may have aided in decreasing gal-1P 
toxicity by converting some gal-1P to UDP-gal (Lai et al., 2003). This would not 
necessarily be a wise option for treatment though, as gal-1P is a competitive inhibitor of 
hUGP2 and would impair UDP-glucose production, only creating further complications 
in galactosemic cells. Not only was UDP-gal production less than normal in GALT-
deficient cells, but UDP-glu was also found to be present at levels as low as 25% of that 
in a healthy individual. Restoration of GALT activity in galactosemic cells was found to 
increase levels of UDP-gal and UDP-glu to that of a healthy individual and decrease the 
accumulation of gal-1P, leading to the conclusion that GALT-deficiency causes a 
decrease in UDP-hexose concentrations in affected cells. It was also concluded that gal-
1P plays a vital role in the decrease of UDP-glu in galactosemic individuals, as it was 
discovered that gal-1P is a competitive inhibitor of hUGP2 and will stop the production 
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of UDP-glu by hUGP2 when present at high concentrations such as those found to be 
associated with galactosemia (Lai et al., 2003).  
Broadening the study of abnormal galactosemic glycans, Liu et al. characterized 
both the N- and O-linked glycomes (all sugar moieties present) of plasma proteins from 
galactosemic individuals, ranging from neonatal age to children and adults with 
determined outcomes. Results showed that the composition of N- and O-linked glycans 
of older children and adults with galactosemia following a galactose-restricted diet were 
close to if not exactly that of healthy individuals, and there appeared to be no connection 
between glycosylation defects and severity of patient outcome, provided the patient 
followed a strict galactose-free diet.  
Although the research with abnormal glycan composition in galactosemic 
individuals appears to show that diet can resolve these abnormalities, the question that 
remains to be investigated is whether abnormal glycans that have not yet been eliminated 
by dietary treatment in the galactosemic neonate can lead to the long-term negative 
outcomes of galactosemic patients, and whether time of galactose exposure affects 
outcome severity.  
Treatment 
Galactosemia, upon diagnosis soon after birth, is treated immediately by the 
removal of galactose from the diet. Although this eliminates the acute symptoms of the 
disease, many patients still develop long-term complications, including developmental 
delay, motor abnormalities, and, in women, ovarian failure. Though the exact molecular 
mechanisms causing these complications are not completely understood, ideas for 
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possible drug targets have been proposed, in addition to life-long dietary restriction of 
galactose. 
Diet. The most common and currently most effective form of treatment for 
galactosemia is dietary restriction of galactose consumption. This is primarily manifested 
in the avoidance of lactose, as many foods ingested by humans that contain galactose do 
not contain galactose monomers but rather galactose-glucose disaccharides, or lactose. 
For infants this is especially important, since breast milk contains lactose, and 
galactosemic infants must consume galactose-free formula. Though it was typically 
believed that galactose was only found in the human diet in the form of lactose, there 
have been studies documenting the presence of free galactose in some fruits and 
vegetables. A study by Gross and Acosta in 1991 documented the monomeric galactose 
content of 45 different fruits and vegetables. Results showed that foods like artichoke, 
mushrooms, olives, and peanuts contained less than 0.1 mg of free galactose per 100 g of 
plant tissue, while persimmon, similar to tomato, contains up to 34.5 mg free galactose 
per 100 g plant tissue. Other fruits and vegetables, like dates, papaya, bell pepper, tomato, 
and watermelon were found to have upwards of 10 mg free galactose per 100 g plant 
tissue (Gross & Acosta, 1991). A second study by Gropper and colleagues revealed that 
other fruits and vegetables, such as pineapples, honeydew melon, and blueberries also 
contain significant amounts of free galactose (18.7 mg/100g, 26.7 mg/100g, and 26.2 
mg/100g, respectively), and some baby foods are high in free galactose content and 
therefore unsuitable for a galactose-restricted diet (Gropper, Weese, West, & Gross, 
2000). The maximum galactose content of foods in a galactose-restricted diet is 5 
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mg/100g, and any foods exceeding 20 mg/100g galactose are absolutely prohibited in the 
recommended galactosemic patient diet (Acosta & Ryan, 1997).  
Conclusion 
 Galactose-1-phosphate uridyltransferase (GALT) is an enzyme in the Leloir 
pathway of galactose metabolism, and its function is to produce UDP-galactose from 
galactose-1-phosphate. UDP-gal can continue in galactose metabolism to eventually enter 
glycolysis and produce metabolic energy, or it can be used to synthesize necessary 
glycoconjugates, such as hormones and protein glycans. When cells are deficient in 
GALT, the result is the accumulation of its substrate, gal-1P. Numerous studies have 
shown gal-1P to be toxic when it accumulates to significantly above-normal 
concentrations, but the exact mechanism of gal-1P toxicity and the mechanism of 
galactosemia disease symptoms are not fully understood. Possibilities of pathogenic 
mechanisms in humans involve the UPR, hIMPase, and abnormal glycan composition. 
The UPR is regulated genetically, and galactosemic human cells have been shown to 
upregulate the genes involved in initiating the UPR, a response typically only utilized 
during ER stress due to an abundance of unfolded or improperly folded proteins in the 
ER lumen. hIMPase is an enzyme that plays a crucial role in the PIP2 signaling pathway, 
as it cleaves multiple inositol bisphosphates to produce inositol, a necessary molecule for 
the regeneration of PIP2 and the continuation of an efficient signal response. Studies have 
shown that glycan compositions of enzymes like transferrin and growth factors like 
ERGF are altered and usually truncated compared to the normal glycans in untreated 
galactosemic individuals. Dietary restriction of galactose has been shown to eliminate 
these glycan abnormalities, but there may still be a connection between abnormal glycans 
GALT AND GALACTOSEMIA   27 
before treatment and the presence of long-term complications in most galactosemic 
individuals. Current treatment for galactosemia involves strict dietary restriction of 
galactose, including all foods and drinks known to contain lactose. With continued study 
and investigation into the exact mechanisms of the pathogenesis of galactosemia, a more 
efficient treatment may be discovered to not only eliminate the acute symptoms of 
galactosemia, but also the long-term complications.  
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